CAMLIN FINE SCIENCES LTD.

Camlin Fine Sciences Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1, 2026, until 48 hours after the declaration of the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. This restriction applies to designated persons and their immediate relatives. The specific date for the board meeting to consider these financial results will be communicated later.

Camlin Fine Sciences Limited (CFSL) announced that the French stock market authority (AMF) has granted clearance for its mandatory tender offer for the remaining shares of Vinpai. The offer price is set at EUR 3.60 per share, consistent with the price of CFSL's earlier acquisition of a majority stake in Vinpai. The company has also released the offer document and other related information, making them publicly available on the websites of the AMF, CFSL, and Vinpai. CFSL currently holds 83.82% of Vinpai's share capital and 80.85% of its voting rights.

Camlin Fine Sciences Ltd's board approved the appointment of Mr. Pankaj Pandey as Chief Financial Officer (CFO) effective August 18, 2026. Current CFO, Mr. Santosh Parab, will be re-designated as President – Strategy and Global CFO. The board also approved the appointment of M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditor for the financial year ending March 31, 2027. The company's 33rd Annual General Meeting will be held on August 11, 2026. Audited financial results for the year ended March 31, 2026, with unmodified opinions from the statutory auditor, were also approved.

Camlin Fine Sciences Ltd's board approved the audited financial results for the year ended March 31, 2026. Consolidated revenue from operations stood at ₹1628.69 million. The board also approved the appointment of M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditors for the financial year ending March 31, 2027. Mr. Pankaj Pandey was appointed as CFO, effective August 18, 2026, while Mr. Santosh Parab will be re-designated as President – Strategy and Global CFO.

Camlin Fine Sciences Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026. The results include both consolidated and standalone statements. Kalyaniwalla & Mistry LLP issued unmodified opinions on the audited financial statements. The 33rd Annual General Meeting will be held on August 11, 2026. Additionally, ABK & Associates were appointed as Cost Auditors and Mahajan & Aibara as Internal Auditor for FY27. Mr. Pankaj Pandey was appointed as CFO, effective August 18, 2026, leading to the re-designation of Mr. Santosh Parab to President – Strategy and Global CFO.

Camlin Fine Sciences Ltd has announced the closure of its Diphenol Plant due to geopolitical issues and economic constraints affecting raw material availability and prices. The company had already reduced capacity utilization and secured Hydroquinone imports to mitigate the impact on downstream products. A fire incident also occurred at the plant, causing an estimated loss of ₹2 crore, covered by insurance. Ethyl Vanillin production is expected to restart within 48 hours, and the company does not anticipate any impact on sales of downstream products. The company is evaluating repurposing the Diphenol Plant.

A fire incident occurred at Camlin Fine Sciences' Diphenol Plant on May 23, 2026, around 11:30 p.m. due to a leakage of high-temperature thermic fluid. The fire was extinguished by 12:30 a.m. on May 24, 2026. The incident resulted in an estimated loss of ₹2 crore, including inventory and damage to equipment, which is covered by insurance. Ethyl Vanillin production was temporarily shut down as a precaution but is expected to restart within 48 hours. The company does not anticipate any impact on sales of downstream products. The Diphenol plant was already undergoing shutdown due to geopolitical and economic constraints affecting raw material availability.

Camlin Fine Sciences Ltd has scheduled a Board of Directors meeting on May 26, 2026, to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The company had previously announced the closure of the Trading Window from April 1, 2026, until 48 hours after the financial results are made public.

Camlin Fine Sciences Ltd. has released the Monitoring Agency Report for the quarter ended March 31, 2026, regarding the utilization of funds raised through its Rights Issue. The report, prepared by India Ratings & Research Private Limited, confirms no deviation in the use of issue proceeds from the stated objectives in the Letter of Offer. The Audit Committee reviewed and approved the report on May 12, 2026, followed by the Board of Directors on May 15, 2026.

Camlin Fine Sciences Ltd (CFSL) has filed a draft tender offer with the French Stock Markets Authority for a simplified cash tender offer (OPAS) targeting the remaining shares of Vinpai's share capital not held by CFSL. The offer price is EUR 3.60 per Vinpai share, matching the Block Acquisition price. CFSL currently holds 83.82% of Vinpai's share capital and 80.85% of its voting rights. The offer is subject to review by the AMF. Vinpai's Board of Directors has issued a favorable opinion on the OPAS based on an independent expert's report.